On February 15, a delegation including Tess Mak, Regional Director of AIA (a Fortune 500 company), Zeng Xiangbin from Dingrui Jinying Group, Wang Xiaodong, Executive Vice President of China Chuan Shang Association and founder of Jixiang Holding Group, and Yi Long, Secretary-General of the Hunan Chamber of Commerce in the United States and founder/CEO of Shuihan Capital, visited Shenzhen Cell Valley. Our company's Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Deputy General Manager Tang Xiaomeng, Chief Medical Advisor Dr. David Jin, Director of General Affairs Office Wei Zheng, Assistant to the Chairman Fu Yuchen, Head of Marketing Department Sun Rui, and Director of General Office Wang Lu warmly received them.

Accompanied by Professor Shi Yuanyuan, the visiting guests toured the Shenzhen Cell Valley Smart Exhibition Hall, where they gained a detailed understanding of the development history, core technologies, and research achievements of Shenzhen Cell Valley. Subsequently, they visited the production workshops and R&D laboratories, gaining a more intuitive perception of the actual operational processes, production, and quality management systems.

At the symposium, Chairman Shi Yuanyuan first extended a warm welcome to all guests and provided a detailed introduction to the company's core technological advantages. He emphasized that Shenzhen Cell Valley possesses a comprehensive production and quality control system, continuously advancing and refining its expertise in both genetically modified and non-genetically modified cell therapy technologies, with the aim of contributing to the cause of human health. Professor Shi Yuanyuan further elaborated on the pivotal roles of NK cells, stem cells, and exosomes in driving the development of the healthcare industry. NK cells serve as the primary "warriors" in the body, responsible for eliminating abnormal cells such as senescent, virus-infected, and tumor cells. Mesenchymal stem cells (MSCs) not only exhibit multipotent differentiation potential but also facilitate the transfection of exogenous genes and ensure their efficient, long-term expression. Exosomes, as crucial carriers for intercellular communication, demonstrate therapeutic effects including immunomodulation, anti-inflammatory action, anti-fibrosis, inhibition of oxidative stress, and enhancement of angiogenesis. Subsequently, Chairman Shi Yuanyuan shared insights on policy expectations and industry development trends. He stated that with the increasing emphasis on the healthcare industry by the state, relevant policy support will continue to strengthen, providing a favorable external environment for the research and application of cell therapy technologies.

When discussing cooperation with Hong Kong, Chairman Shi Yuanyuan stated that Shenzhen and Hong Kong share geographical proximity and cultural affinity, with extensive collaborative foundations in fields such as technology, finance, and healthcare. Shenzhen Cell Valley has always placed great emphasis on cooperation and exchanges with relevant institutions in Hong Kong. Currently, Shenzhen Cell Valley is establishing a subsidiary in the Qianhai Free Trade Zone—Deep Harbour Cell Valley—specifically targeting the Greater Bay Area, particularly Hong Kong. This initiative aims to promote the research, development, and application of cell therapy technologies through more closely aligned and targeted cooperation mechanisms, thereby fostering the coordinated development of the health industry in both regions.

Director Mak from AIA Insurance highlighted the company's role as Asia's largest life insurance group in serving high-net-worth individuals, while expressing eagerness to deepen collaboration with medical institutions and enterprises in mainland China, particularly in Shenzhen. Director Mak noted that AIA Insurance anticipates close cooperation with Shenzhen Cell Valley to provide more advanced and effective healthcare services for group clients. Other attendees also contributed insights, engaging in in-depth discussions on strengthening Shenzhen-Hong Kong cooperation in the health industry and advancing research and application of cell therapy technologies. Participants unanimously agreed that this exchange and inspection activity not only deepened mutual understanding and trust but also laid a solid foundation for future collaboration.

This interactive exchange between Shenzhen and Hong Kong enterprises not only demonstrated the leading position and influence of Shenzhen Cell Valley in the field of the health industry, but also injected new vitality into the cooperation and exchanges between the two regions in this domain. In the future, Shenzhen Cell Valley will continue to leverage its advantages, persistently explore innovations, and strive to make greater contributions to the cause of human health.